
PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...





